P-gp is often overexpressed in cancer cells, contributing to the development of MDR. This phenomenon occurs when cancer cells become resistant to a wide array of chemotherapeutic drugs, making the treatment less effective. P-gp accomplishes this by actively pumping out cytotoxic drugs from the cancer cells, thereby reducing their intracellular concentrations and efficacy.
